Loading...

CYBERDYNE Inc.

CYBQYPNK
Healthcare
Medical - Devices
$1.33
$0.00(0.00%)

CYBERDYNE Inc. (CYBQY) Financial Performance & Income Statement Overview

Explore the financials of CYBERDYNE Inc. (CYBQY), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
0.69%
0.69%
Operating Income Growth
13.82%
13.82%
Net Income Growth
60.91%
60.91%
Operating Cash Flow Growth
49.41%
49.41%
Operating Margin
-26.03%
26.03%
Gross Margin
54.13%
54.13%
Net Profit Margin
-13.16%
13.16%
ROE
-1.43%
1.43%
ROIC
-2.40%
2.40%

CYBERDYNE Inc. (CYBQY) Income Statement & Financial Overview

Analyze CYBERDYNE Inc.’s CYBQY earnings with segmented quarterly and yearly financial statement figures.

MetricQ3 2024Q2 2024Q1 2024Q4 2023
Revenue$1.03B$988.00M$1.16B$915.00M
Cost of Revenue$449.00M$528.00M$553.00M$606.00M
Gross Profit$577.00M$460.00M$602.00M$309.00M
Gross Profit Ratio$0.56$0.47$0.52$0.34
R&D Expenses$294.00M$203.00M$205.00M$241.00M
SG&A Expenses$615.00M$685.00M$681.00M$592.00M
Operating Expenses$788.00M$1.02B$756.00M$706.00M
Total Costs & Expenses$1.24B$1.55B$1.31B$1.31B
Interest Income$0.00$0.00$139.00M$618.00M
Interest Expense$0.00$0.00$4.00M$184.00M
Depreciation & Amortization$151.00M$144.00M$154.00M$196.00M
EBITDA-$62.00M-$200.00M$161.00M-$298.00M
EBITDA Ratio-$0.06-$0.20$0.14$0.27
Operating Income-$211.00M-$558.00M-$154.00M-$396.00M
Operating Income Ratio-$0.21-$0.56-$0.13-$0.43
Other Income/Expenses (Net)$134.00M$351.00M$147.00M$337.00M
Income Before Tax-$77.00M-$207.00M-$7.00M-$59.00M
Income Before Tax Ratio-$0.08-$0.21-$0.006-$0.06
Income Tax Expense-$3.00M$169.00M$2.00M$340.00M
Net Income-$79.00M-$316.00M$11.00M-$366.00M
Net Income Ratio-$0.08-$0.32$0.010-$0.40
EPS-$0.37-$1.50$0.05-$1.70
Diluted EPS-$0.37-$1.50$0.05-$1.70
Weighted Avg Shares Outstanding$211.13M$210.37M$211.13M$214.79M
Weighted Avg Shares Outstanding (Diluted)$211.13M$211.13M$220.00M$214.79M

Over the past four quarters, CYBERDYNE Inc. demonstrated steady revenue growth, increasing from $915.00M in Q4 2023 to $1.03B in Q3 2024. Operating income reached -$211.00M in Q3 2024, maintaining a consistent -21% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$62.00M, reflecting operational efficiency. Net income rose to -$79.00M, with EPS at -$0.37. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;